Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis

Clinical Pharmacokinetics

Volumn 41, Issue 9, 2002, Pages 681-690

  Lopez Cortes, Luis F ^a   Ruiz Valderas, Rosa ^a   Pompyo, Viciana ^a   Aristides, Alarcon Gonzalez ^a   Gomez Mateos, Jesus ^b   Leon Jimenez, Eva ^a   Sarasa Nacenta, Maria ^c   Lopez Pua, Yolanda ^c   Pachon, Jeronimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ISONIAZID; NUCLEOSIDE DERIVATIVE; PYRAZINAMIDE; RIFAMPICIN; RIFATER; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUBERCULOSIS;

EID: 0036060766     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241090-00004     Document Type: Article

References (24)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. The treatment of tuberculosis in HIV-infected persons
3. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
4. Clinical update: Impact of HIV protease inhibitors on the treatment of HIV infected tuberculosis patients with rifampin
5. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
6. Ritonavir enables combined therapy with rifampin and saquinavir
7. Randomized trial of abacavir (ABC) in combination with indinavir (IDV) and efavirenz (EFV) in HIV-infected patients (Pts) with nucleoside analog experience (NRTI exp)
8. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
9. Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers
10. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection
11. High-performance liquid chromatographic assay of rifampicin in human serum
12. Pharmacokinetics of efavirenz alone and in combination therapy with nelfinavir in HIV-infected patients
13. Metabolism and pharmacokinetics of the antibiotic rifampin
14. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
15. Rifampin kinetics in undernutrition
16. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease
17. Low antituberculosis drug concentrations in patients with AIDS
18. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection
19. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
20. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients